tinzaparin (Innohep)
Jump to navigation
Jump to search
Introduction
Tradename: Innohep. withdrawn from the U.S. market[5]
(see low molecular weight heparin)
Indications
* equivalent to dalteparin
Dosage
- 175 units/kg SC QD (full anticoagulation)
Adverse effects
- increased mortality in patients > 70 with renal insufficiency[3]
see LMW heparin[4]
- drug adverse effects of LMW heparin
- drug adverse effects of anticoagulants
- drug adverse effects of antithrombotic agent(s)
Notes
Equivalent to dalteparin for treatment of:
More general terms
References
- ↑ Prescriber's Letter 7(12):72 2000 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=161206&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ Journal Watch 25(10):78, 2005 Wells PS, Anderson DR, Rodger MA, Forgie MA, Florack P, Touchie D, Morrow B, Gray L, O'Rourke K, Wells G, Kovacs J, Kovacs MJ. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism. Arch Intern Med. 2005 Apr 11;165(7):733-8. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15824291
- ↑ Jump up to: 3.0 3.1 FDA MedWatch http://www.fda.gov/medwatch/safety/2008/safety08.htm#Innohep
- ↑ Jump up to: 4.0 4.1 Medical Knowledge Self Assessment Program (MKSAP) 16, American College of Physicians, Philadelphia 2012
- ↑ Jump up to: 5.0 5.1 5.2 Lee AYY et al. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: A randomized clinical trial. JAMA 2015 Aug 18; 314:677. PMID: https://www.ncbi.nlm.nih.gov/pubmed/26284719